Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison
Abstract Safinamide and rasagiline are adjuncts to levodopa for the motor fluctuations of Parkinson’s Disease (PD). However, there remains a scarcity of head-to-head studies that directly compare safinamide and rasagiline. This study compared safinamide and rasagiline as adjuncts to levodopa in Chin...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-94960-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063766555721728 |
|---|---|
| author | Yuyan Tan Qianqian Wei Pingyi Xu Enxiang Tao Lijiao Wang Carlo Cattaneo Huifang Shang Shengdi Chen |
| author_facet | Yuyan Tan Qianqian Wei Pingyi Xu Enxiang Tao Lijiao Wang Carlo Cattaneo Huifang Shang Shengdi Chen |
| author_sort | Yuyan Tan |
| collection | DOAJ |
| description | Abstract Safinamide and rasagiline are adjuncts to levodopa for the motor fluctuations of Parkinson’s Disease (PD). However, there remains a scarcity of head-to-head studies that directly compare safinamide and rasagiline. This study compared safinamide and rasagiline as adjuncts to levodopa in Chinese PD patients with motor fluctuations by matching-adjusted indirect comparison. Baseline age, sex, BMI, and OFF time were adjusted for matching. Efficacy outcomes were the mean changes in total daily OFF time, UPDRS III, and PDQ-39 from baseline to week 16, which calculated by a weighted covariance model. Safety outcomes included rates of AEs, SAEs, and DCAEs. Bucher method was used for mean difference (MD) of efficacy and odds ratio (OR) of safety outcomes. Combination therapy of safinamide 50-100 mg/day and levodopa significantly reduced the mean total daily OFF time by 0.7 h (− 1.40 to − 0.02) compared to the combination therapy of rasagiline 1 mg/day and levodopa. Safinamide more effectively reduced UPDRS III (− 2.9, − 5.28 to − 0.52). Changes in PDQ-39 scores indicated a trend toward greater improvement in safinamide. There was no significant difference in safety outcomes. Compared to rasagiline, the combined therapy of safinamide and levodopa could significantly improve motor fluctuations for PD patients in China, without compromising safety. |
| format | Article |
| id | doaj-art-e4e8731b812c4dec9831a31bb5ccb693 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e4e8731b812c4dec9831a31bb5ccb6932025-08-20T02:49:30ZengNature PortfolioScientific Reports2045-23222025-03-011511710.1038/s41598-025-94960-9Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparisonYuyan Tan0Qianqian Wei1Pingyi Xu2Enxiang Tao3Lijiao Wang4Carlo Cattaneo5Huifang Shang6Shengdi Chen7Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Neurology, West China Hospital of Sichuan UniversityDepartment of Neurology, The First Affiliated Hospital of Guangzhou Medical UniversityDepartment of Neurology, Sun Yat-sen Memorial HospitalMedical and Regulatory Department, Hainan Zambon Pharmaceutical Co., LtdMedical Department, Zambon SpADepartment of Neurology, West China Hospital of Sichuan UniversityDepartment of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineAbstract Safinamide and rasagiline are adjuncts to levodopa for the motor fluctuations of Parkinson’s Disease (PD). However, there remains a scarcity of head-to-head studies that directly compare safinamide and rasagiline. This study compared safinamide and rasagiline as adjuncts to levodopa in Chinese PD patients with motor fluctuations by matching-adjusted indirect comparison. Baseline age, sex, BMI, and OFF time were adjusted for matching. Efficacy outcomes were the mean changes in total daily OFF time, UPDRS III, and PDQ-39 from baseline to week 16, which calculated by a weighted covariance model. Safety outcomes included rates of AEs, SAEs, and DCAEs. Bucher method was used for mean difference (MD) of efficacy and odds ratio (OR) of safety outcomes. Combination therapy of safinamide 50-100 mg/day and levodopa significantly reduced the mean total daily OFF time by 0.7 h (− 1.40 to − 0.02) compared to the combination therapy of rasagiline 1 mg/day and levodopa. Safinamide more effectively reduced UPDRS III (− 2.9, − 5.28 to − 0.52). Changes in PDQ-39 scores indicated a trend toward greater improvement in safinamide. There was no significant difference in safety outcomes. Compared to rasagiline, the combined therapy of safinamide and levodopa could significantly improve motor fluctuations for PD patients in China, without compromising safety.https://doi.org/10.1038/s41598-025-94960-9SafinamideRasagilineLevodopaMonoamine oxidase type B inhibitorsMatching-adjusted indirect comparisonParkinson’s disease |
| spellingShingle | Yuyan Tan Qianqian Wei Pingyi Xu Enxiang Tao Lijiao Wang Carlo Cattaneo Huifang Shang Shengdi Chen Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison Scientific Reports Safinamide Rasagiline Levodopa Monoamine oxidase type B inhibitors Matching-adjusted indirect comparison Parkinson’s disease |
| title | Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison |
| title_full | Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison |
| title_fullStr | Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison |
| title_full_unstemmed | Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison |
| title_short | Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison |
| title_sort | comparing the efficacy and safety of safinamide with rasagiline in china parkinson s disease patients with a matching adjusted indirect comparison |
| topic | Safinamide Rasagiline Levodopa Monoamine oxidase type B inhibitors Matching-adjusted indirect comparison Parkinson’s disease |
| url | https://doi.org/10.1038/s41598-025-94960-9 |
| work_keys_str_mv | AT yuyantan comparingtheefficacyandsafetyofsafinamidewithrasagilineinchinaparkinsonsdiseasepatientswithamatchingadjustedindirectcomparison AT qianqianwei comparingtheefficacyandsafetyofsafinamidewithrasagilineinchinaparkinsonsdiseasepatientswithamatchingadjustedindirectcomparison AT pingyixu comparingtheefficacyandsafetyofsafinamidewithrasagilineinchinaparkinsonsdiseasepatientswithamatchingadjustedindirectcomparison AT enxiangtao comparingtheefficacyandsafetyofsafinamidewithrasagilineinchinaparkinsonsdiseasepatientswithamatchingadjustedindirectcomparison AT lijiaowang comparingtheefficacyandsafetyofsafinamidewithrasagilineinchinaparkinsonsdiseasepatientswithamatchingadjustedindirectcomparison AT carlocattaneo comparingtheefficacyandsafetyofsafinamidewithrasagilineinchinaparkinsonsdiseasepatientswithamatchingadjustedindirectcomparison AT huifangshang comparingtheefficacyandsafetyofsafinamidewithrasagilineinchinaparkinsonsdiseasepatientswithamatchingadjustedindirectcomparison AT shengdichen comparingtheefficacyandsafetyofsafinamidewithrasagilineinchinaparkinsonsdiseasepatientswithamatchingadjustedindirectcomparison |